Update shared on01 Aug 2025
Fair value Increased 2.77%The consensus analyst price target for Gland Pharma has been revised downward, primarily due to a lower forecasted future P/E multiple while revenue growth expectations remain stable, resulting in a new target of ₹1662.
What's in the News
- Brookfield Corporation and EQT AB are in advanced talks to acquire Gland Pharma from Fosun Group, with CVC Capital Partners also exploring a potential deal; the rising share price and macro/geopolitical headwinds could hinder the transaction, which could reach up to INR 257,110 million ($3 billion) if the open offer is fully subscribed.
- Gland Pharma received USFDA approval for its Angiotensin II Acetate Injection, securing 180 days of generic exclusivity as First-to-File, for a product with US annual sales of approximately $58 million.
- The board approved the grant of 15,347 employee stock options to one employee under the 2025 Employee Stock Options Scheme.
- Gland Pharma announced an annual dividend of INR 18.00 per share, payable in September 2025.
- The company is expected to report Q1 2026 results on August 1, 2025.
Valuation Changes
Summary of Valuation Changes for Gland Pharma
- The Consensus Analyst Price Target has fallen from ₹1774 to ₹1662.
- The Future P/E for Gland Pharma has fallen from 29.70x to 27.82x.
- The Consensus Revenue Growth forecasts for Gland Pharma remained effectively unchanged, at 13.0% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.